Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
Portfolio Pulse from
ESK-001 showed strong clinical responses and was well tolerated over 52 weeks in a Phase 2 trial for psoriasis, as presented at the AAD 2025 meeting.
March 08, 2025 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ALMS's ESK-001 demonstrated strong clinical responses and good tolerance in a 52-week Phase 2 trial for psoriasis, presented at AAD 2025.
The positive results from the Phase 2 trial of ESK-001 are likely to boost investor confidence in ALMS, as the drug shows promise in treating psoriasis. This could lead to increased interest and potential stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100